102996-25-8

Basic information

• Product Name: 5-amino-1-(2,4-difluorophenyl)-1H-pyrazole-4-carbonitrile
• Synonyms: 5-amino-1-(2,4-difluorophenyl)-1H-pyrazole-4-carbonitrile
• CAS NO: 102996-25-8
• Molecular Formula: C₁₀H₆F₂N₄
• Molecular Weight: 220.1782464
• Mol File: 102996-25-8.mol
• Article Data: 7

Chemical Properties

• Melting Point: 190-191 °C
• Boiling Point: 386.9±42.0 °C(Predicted)
• Appearance: /
• Density: 1.45±0.1 g/cm3(Predicted)
• PKA: -1.56±0.10(Predicted)
• CAS DataBase Reference: 5-amino-1-(2,4-difluorophenyl)-1H-pyrazole-4-carbonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 5-amino-1-(2,4-difluorophenyl)-1H-pyrazole-4-carbonitrile(102996-25-8)
• EPA Substance Registry System: 5-amino-1-(2,4-difluorophenyl)-1H-pyrazole-4-carbonitrile(102996-25-8)

Safety Data

• Hazardous Substances Data: 102996-25-8(Hazardous Substances Data)

Usage

General Description

5-amino-1-(2,4-difluorophenyl)-1H-pyrazole-4-carbonitrile is a chemical compound with the molecular formula C9H5F2N5. It is a pyrazole derivative containing an amino group and a carbonitrile group. 5-amino-1-(2,4-difluorophenyl)-1H-pyrazole-4-carbonitrile is used in the development of pharmaceuticals and agrochemicals due to its potential biological and pharmacological activities. It may have applications in the treatment of various diseases and as an herbicide or pesticide. Its precise uses and properties can vary depending on the specific research and development being conducted.

Upstream product

• 40594-30-7 2,4-difluorophenylhydrazine 
• 123-06-8 Ethoxymethylenemalononitrile 
• 40594-29-4 (2,4-difluorophenyl)hydrazinium chloride 

Downstream Products

• 1006597-07-4 C₁₀H₈F₂N₄O 
• 1452871-41-8 C₁₄H₁₁F₂N₅O 
• 1452871-38-3 C₁₃H₉F₂N₅O 
• 1256346-78-7 1-(2,4-difluorophenyl)-6-oxo-6,7-dihydro-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid 
• 1080573-41-6 5-bromo-1-(2,4-difluorophenyl)-1H-pyrazolo[3,4-b]pyridin-6(7H)-one 
• 1220512-69-5 ethyl 1-(2,4-difluorophenyl)-6-oxo-6,7-dihydro-1H-pyrazolo[3,4-b]pyridine-5-carboxylate 
• 1220512-63-9 5-amino-1-(2,4-difluorophenyl)-1H-pyrazole-4-carbaldehyde 
• 1153630-24-0 1-(2,4-difluorophenyl)-6-(trifluoromethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 
• 1153630-25-1 1-(2,4-difluorophenyl)-6-(fluoromethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 
• 936758-10-0 1-(2,4-difluorophenyl)-6-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine 

Relevant articles and documents

Microwave-assisted efficient synthesis of pyrazole-fibrate derivatives as stimulators of glucose uptake in skeletal muscle cells

The design and synthesis of a series of pyrazolo[3,4-d]pyrimidinones containing fibrate side chains have been accomplished by utilizing the concept of molecular hybridization. All the synthesized compounds were evaluated for the glucose uptake stimulatory effect in L6 rat skeletal muscle cells. Four compounds (3f, 3g, 3j and 3q) were found to show significant stimulation of glucose uptake. Further these four compounds have been examined for their Glut4 translocation stimulatory effect in L6-Glut4myc myotubes. Compound 3q was found to exert maximum increase in GLUT4myc translocation.

Discovery and evaluation of 7- lkyl-1,5-bis-aryl-pyrazolopyridinones as Highly potent, selective, and orally efficacious inhibitors of p38α mitogen-activated protein kinase

The p38α mitogen-activated protein (MAP) kinase is a central signaling molecule in many proinflammatory pathways, regulating the cellular response to a multitude of external stimuli including heat, ultraviolet radiation, osmotic shock, and a variety of cytokines especially interleukin-1- and tumor necrosis factor α. Thus, inhibitors of this enzyme are postulated to have significant therapeutic potential for the treatment of rheumatoid arthritis, inflammatory bowel disease, and Crohn's disease, as well as other diseases where aberrant cytokine signaling is the driver of disease. In this communication, we describe a novel class of 7-alkyl-1,5-bis-aryl- pyrazolopyridinone-based p38α inhibitors. In particular, compound 3f is highly potent in the enzyme and cell-based assays, selective in an Ambit kinase screen, and efficacious (ED50 - 0.01 mg/kg) in the rat collagen induced arthritis (CIA) model.

NOVEL COMPOUNDS

The present invention provides compounds of formula (I): a process for their preparation, to pharmaceutical compositions comprising the compounds and the preparation of said compositions, to intermediates, and to use of the compounds for the manufacture of a medicament for therapeutic treatment, particularly for the treatment of inflammation and/or allergic conditions.